Related Experiment Videos
Atorvastatin and diabetic vascular complications
Sho-ichi Yamagishi1, Takanori Matsui, Kazuo Nakamura
1Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
Current Pharmaceutical Design
|April 14, 2006
Summary
Atorvastatin, a widely used statin, effectively lowers LDL cholesterol and cardiovascular risks. This review explores its potential benefits beyond lipid reduction for preventing diabetic vascular complications.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Statins, including atorvastatin, inhibit HMG-CoA reductase, lowering LDL cholesterol and cardiovascular event risk.
- Atorvastatin's pleiotropic effects, beyond lipid-lowering, may contribute to cardiovascular protection.
- Diabetic vascular complications significantly increase morbidity and mortality, with treatment mechanisms needing further elucidation.
Purpose of the Study:
- To review the efficacy and safety of atorvastatin in treating diabetic vascular complications.
- To discuss the potential vasculoprotective properties of atorvastatin in diabetic patients.
Main Methods:
- Literature review focusing on atorvastatin's role in diabetic vascular complications.
- Analysis of clinical trial data and pharmacological mechanisms.
Main Results:
- Atorvastatin is widely used for hypercholesterolemia and shows cardiovascular benefits.
- Evidence suggests potential benefits of atorvastatin in mitigating diabetic vascular complications, though not fully elucidated.
- Pleiotropic effects of atorvastatin may contribute to its protective actions.
Conclusions:
- Atorvastatin demonstrates efficacy in managing hypercholesterolemia and reducing cardiovascular events.
- Further research is warranted to fully understand and confirm atorvastatin's role in preventing and treating diabetic vascular complications.
- Atorvastatin's vasculoprotective properties may offer significant benefits for diabetic patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:22Complications of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...